- Home
- SCLXW vs EIIA Comparison
SCLXW vs EIIA Comparison
Compare SCLXW & EIIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCLXW | EIIA |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | |
| Employees | 34 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCLXW | EIIA |
|---|---|---|
| Price | $0.17 | $25.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.4K | 2.0K |
| Earning Date | 03-07-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,152,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.02 | N/A |
| 52 Week Low | $0.05 | $24.65 |
| 52 Week High | $0.64 | $26.33 |
Technical Indicators
Market Signals| Indicator | SCLXW | EIIA |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 50.81 |
| Support Level | $0.11 | $25.04 |
| Resistance Level | $0.18 | $25.28 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 76.94 | 53.25 |
Price Performance
Historical ComparisonAbout SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
About EIIA Eagle Point Institutional Income Fund
Eagle Point Institutional Income Fund is a closed-end investment company. Its investment objective is to generate high current income, with a secondary objective to generate capital appreciation.